The Journal of Hematology Oncology Pharmacy (the Journal) follows the recommendations of the International Committee of Medical Journal Editor’s (ICMJE) uniform requirements for manuscript preparation, review, editing, and publication. The full ICMJE recommendations can be accessed at www.icmje.org/urm_main.html.
The Journal of Hematology Oncology Pharmacy is an independent, peer-reviewed journal founded in 2011 to provide hematology and oncology pharmacy practitioners and other healthcare professionals with high-quality peer-reviewed information relevant to hematologic and oncologic conditions to help them optimize drug therapy for patients.
All articles carry a Conflict of Interest Statement and a Funding Source statement if the article/study was funded by an outside entity. The editors retain complete authority over the editorial process of all articles published in the Journal.
Articles are edited for style and sense; all data and facts cited are verified. Authors must respond fully to all queries from the editors, regardless of the content of the queries.
Articles that are accepted for publication are scheduled by the editors for a quick and timely publication within 1 to 3 months.
The co-editors-in-chief and the section editors have full authority over the editorial content published in the Journal. No outside intervention or commercial considerations can influence, directly or indirectly, the selection, evaluation, and scheduling of individual articles. The decision to publish an article depends entirely on the merit of the information and its relevance to the Journal’s editorial objectives and may not in any way involve commercial or financial considerations.
The editorial advisory board and other experts serving as reviewers have full independence in the peer-review process and in their recommendations for accepting or rejecting an article, as well as the type of comments they provide. Article reviews are done in a double-blind fashion: all authorship information is blinded to the reviewers and reviewers’ information is blinded to authors, but any funding source for the research/article is provided to reviewers.
If correction to a published article is needed, the Journal publishes the correction as soon as possible, detailing the changes from the original version. The correction is listed in the Table of Contents in the print issue, as well as online. Readers are encouraged to submit comments or critiques of any article. All relevant comments are published in the print journal and online and authors are asked to respond to such comments.
The manuscript review process is confidential and cannot be shared with anyone who is not directly involved in that process. The editors and reviewers may not share any information regarding the submission of an article, or any aspect of the article, before publication. The peer-review process is conducted with full confidentiality: reviewers and the editors may not discuss the article submission, or mention the topic or the review to anyone other than the editors. The information contained within a submitted manuscript is strictly confidential and cannot be discussed with anyone other than the authors. The reviewers may not discuss the information in the article or their review with anyone other than the editors.
The Journal of Hematology Oncology Pharmacy adheres to the ICMJE authorship criteria. All authors must meet the 4 criteria outlined by the ICMJE for authorship, which are available at www.icmje.org. It is the responsibility of the authors to decide who can be listed as an author based on those 4 criteria. Contributors who do not meet all 4 criteria should be acknowledged for their contribution in a separate statement. See Instructions for Authors for complete details of submitting a manuscript and the requirements for adhering to publishing policies.
The corresponding author must be available to communicate with the editors during the entire submission, peer-review process, and manuscript preparation/publication process, as well as be prepared to respond to any potential critiques or requests after the publication of the article.
It is the responsibility of the authors to ensure the independence of the content and to make sure that the funding entity did not influence the content of the article or the interpretation of the results.
See Instructions for Authors for details regarding manuscript preparation, requirements, and procedures.
Conflict of Interest
Conflict of interest involves real or potential financial or other personal considerations related to authors or reviewers that may compromise or bias the professional judgment and objectivity of the article. The Journal requires all authors to individually complete and sign a Disclosure Form (see Instructions for Author) and declare any real or potential conflicts of interest relevant to the work under consideration that may interfere with the interpretation of the work, to avoid the potential for bias. A conflict of interest statement appears at the end of each published article.
The authors are responsible for ensuring that the funding entity did not influence the content of the article or the interpretation of the results.
Reviewers with potential or real conflicts must excuse themselves from the review of the particular article.
Identifying personal information, such as patients’ names, initials, or hospital numbers, should not be included in the submitted article, unless the information is essential for the accuracy of the article and the patient (or parent or guardian) has given written informed consent to publish that information. In this case, the patient must be shown the manuscript and the way the information is being used. Authors should provide a signed informed consent when submitting the article and remove any identifying details that are not essential for the purpose of the article.
Authors should obtain informed consent if there is any doubt about the complete anonymity of the information. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors and editors must make sure that the alterations do not distort the scientific meaning.
Human and Animal Rights
When reporting experiments on human subjects, the authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. When in doubt, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, the authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.